Clinical Trial Update: STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma [Phase 1, Phase 2]

View source ↗

Summary

This completed Phase 1/2 trial evaluated STA-4783 in combination with paclitaxel versus paclitaxel alone in patients with melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• STA-4783 (STA-4783)

Snippet

Sponsor: Synta Pharmaceuticals Corp. | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED